199 related articles for article (PubMed ID: 38061621)
1. Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive review.
Siriratnam P; Huda S; Butzkueven H; van der Walt A; Jokubaitis V; Monif M
Autoimmun Rev; 2024 Feb; 23(2):103499. PubMed ID: 38061621
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder.
Shimizu Y; Fujihara K; Ohashi T; Nakashima I; Yokoyama K; Ikeguch R; Takahashi T; Misu T; Shimizu S; Aoki M; Kitagawa K
Mult Scler; 2016 Oct; 22(11):1413-1420. PubMed ID: 25921053
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy-Related Attack in Neuromyelitis Optica Spectrum Disorder With AQP4-IgG: A Single-Center Study and Meta-Analysis.
Deng S; Lei Q; Lu W
Front Immunol; 2021; 12():800666. PubMed ID: 35069584
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
Nour MM; Nakashima I; Coutinho E; Woodhall M; Sousa F; Revis J; Takai Y; George J; Kitley J; Santos ME; Nour JM; Cheng F; Kuroda H; Misu T; Martins-da-Silva A; DeLuca GC; Vincent A; Palace J; Waters P; Fujihara K; Leite MI
Neurology; 2016 Jan; 86(1):79-87. PubMed ID: 26581304
[TBL] [Abstract][Full Text] [Related]
5. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
6. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
[TBL] [Abstract][Full Text] [Related]
7. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder.
Collongues N; Alves Do Rego C; Bourre B; Biotti D; Marignier R; da Silva AM; Santos E; Maillart E; Papeix C; Palace J; Leite MIS; De Seze J
Neurology; 2021 Apr; 96(15):e2006-e2015. PubMed ID: 33627499
[TBL] [Abstract][Full Text] [Related]
9. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
Fujihara K; Cook LJ
Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
[TBL] [Abstract][Full Text] [Related]
11. A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD).
Leite MI; Panahloo Z; Harrison N; Palace J
Mult Scler Relat Disord; 2023 Jul; 75():104760. PubMed ID: 37224631
[TBL] [Abstract][Full Text] [Related]
12. Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management.
Shosha E; Pittock SJ; Flanagan E; Weinshenker BG
Mult Scler; 2017 Dec; 23(14):1808-1817. PubMed ID: 29154728
[TBL] [Abstract][Full Text] [Related]
13. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
14. Neuromyelitis optica spectrum disorders: still evolving and broadening.
Fujihara K
Curr Opin Neurol; 2019 Jun; 32(3):385-394. PubMed ID: 30893099
[TBL] [Abstract][Full Text] [Related]
15. Neuromyelitis optica spectrum disorders in South of Tunisia: A rare entity with low seroprevalence of anti-aquaporin 4 autoantibodies.
Mejdoub S; Feki S; Dammak M; Farhat N; Hdiji O; Boukthir S; Hachicha H; Mhiri C; Masmoudi H
Rev Neurol (Paris); 2020 May; 176(4):261-267. PubMed ID: 31668529
[TBL] [Abstract][Full Text] [Related]
16. Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.
Doubrovinskaja S; Korporal-Kuhnke M; Jarius S; Haas J; Wildemann B
J Neurol; 2024 May; 271(5):2866-2870. PubMed ID: 37962590
[TBL] [Abstract][Full Text] [Related]
17. Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region.
Dale GH; Svendsen KB; Gjelstrup MC; Christensen T; Houen G; Nielsen E; Bek T; Petersen T
Acta Neurol Scand; 2018 Jun; 137(6):582-588. PubMed ID: 29359475
[TBL] [Abstract][Full Text] [Related]
18. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
Alves Do Rego C; Collongues N
Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
[TBL] [Abstract][Full Text] [Related]
19. Overcoming the challenges in diagnosis of AQP4-IgG positive neuromyelitis optica spectrum disorders in resource poor settings using an indigenized and cost effective cell based assay.
Pandit L; Malli C; D'Cunha A; Sudhir A
J Neuroimmunol; 2021 Nov; 360():577706. PubMed ID: 34507014
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging in neuromyelitis optica spectrum disorder.
Clarke L; Arnett S; Lilley K; Liao J; Bhuta S; Broadley SA
Clin Exp Immunol; 2021 Dec; 206(3):251-265. PubMed ID: 34080180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
